Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECLINE: Imatinib Continuation vs Nilotinib in CML
NCT02174445Phase 3Terminated
- Start
- Mar 2014
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nilotinib in chronic myeloid leukemia (CML). Started Mar 2014; status: terminated.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02174445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174445.